Evaluation of cilofungin, a lipopeptide antifungal agent, in vitro against fungi isolated from clinical specimens
- 1 August 1989
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 33 (8) , 1391-1392
- https://doi.org/10.1128/aac.33.8.1391
Abstract
Cilofungin (LY121019) is a new lipopeptide antifungal drug. We tested this drug against 141 pathogenic fungal isolates. All fungal species were tested by broth dilution at 35 degrees C. Malassezia furfur was tested by agar dilution. The results demonstrate the specificity of cilofungin activity. Candida albicans, Candida tropicalis, and Malassezia pachydermatis were highly susceptible, whereas Candida parapsilosis, Candida pseudotropicalis, Candida krusei, Torulopsis glabrata, Blastomyces dermatitidis, Cryptococcus neoformans, Aspergillus species, M. furfur, and Paracoccidioides brasiliensis were more resistant.This publication has 7 references indexed in Scilit:
- Initial Experience in Therapy for Progressive Mycoses with Itraconazole, the First Clinically Studied TriazoleClinical Infectious Diseases, 1987
- In vitro and in vivo anti-Candida activity and toxicology of LY121019.The Journal of Antibiotics, 1984
- LYSIS OF GROWING YEAST-FORM CELLS OF CANDIDA-ALBICANS BY ECHINOCANDIN - A CYTOLOGICAL STUDY1981
- Growth of Paracoccidioides brasiliensis yeast phase in a chemically defined culture mediumJournal of Clinical Microbiology, 1980
- Antimicrobial Susceptibility Testing of Yeasts: a Turbidimetric Technique Independent of Inoculum SizeAntimicrobial Agents and Chemotherapy, 1976
- Obfuscation of the Activity of Antifungal Antimicrobics by Culture MediaThe Journal of Infectious Diseases, 1972